GlassScriptPhysician profile
Nicole D Taylor
NPI 1083159040
$3,583.75
in general payments reported to CMS, 2019-2025
22 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $455 · 2023: $856 · 2024: $1,055 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $361.02 | 2024-2025 | Uzedy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $339.86 | 2022-2025 | Strensiq |
| Abbvie INC. | $250.00 | 2022-2023 | |
| Novo Nordisk INC | $245.07 | 2023-2025 | Wegovy |
| Genzyme Corporation | $240.35 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $198.05 | 2024-2025 | |
| Dexcom, INC. | $154.25 | 2024 | Dexcom G7 Gss (161) |
| Janssen Biotech, INC. | $136.78 | 2025 | |
| Gilead Sciences, INC. | $133.35 | 2025 | Epclusa |
| Edwards Lifesciences Corporation | $125.00 | 2025 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Amgen INC. | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2025 | |
| Neurelis, INC. | $123.56 | 2024 | Valtoco |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
| Sage Therapeutics, LLC | $118.36 | 2023 | |
| Janssen Pharmaceuticals, INC | $115.06 | 2024 | Spravato |
| Viiv Healthcare Company | $102.30 | 2025 | Apretude |
| Phathom Pharmaceuticals, INC. | $101.66 | 2024 | Voquezna |
| Lilly USA, LLC | $95.43 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.